Targets › IL21
4 programs from 4 companies in 8 trials: 5 Phase 1, 3 Phase 2; Oncology; next expected readout Jun 2027.
Cytokine with immunoregulatory activity. May promote the transition between innate and adaptive immunity. (UniProt, Q9HBE4)
Open in Phaseline: the race on IL21, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hangzhou Converd | hV01 Recombinant vaccinia virus with deletions of viral thymidine kinase (TK) and viral growth | IL21 | Phase 2 | Advanced Pancreatic Cancer; Advanced Solid Tumors | Jun 2027 |
| Daihong Liu | PD-1Ab21-BCMA CAR-T BCMA-targeting CAR-T cells secreting PD-1 antibody and interleukin-21 fusion protein | BCMA, PDCD1, IL21 | Phase 2 | Multiple Myeloma | Jul 2027 |
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | mbIL21 ex vivo-expanded donor-derived NK cells IL-21-engineered natural killer cells for leukemia relapse prophylaxis | IL21 | Phase 2 | Acute Myeloid Leukemia | Oct 2027 |
| M.D. Anderson Cancer Center | Cytokine-treated Veto Cells CAR-T/CAR-NK cell therapy targeting IL-13 receptor alpha-1 and EGFvIII on glioblastoma cel | IL13RA1, EGFR, IL21, TGFBR2, NR3C1, TROP2 | Phase 1 | Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Phase 1; Colorectal Cancer | Dec 2027 |
Acute Myeloid Leukemia (2) Advanced Pancreatic Cancer (1) Advanced Solid Tumors (1) Multiple Myeloma (1) Acute Lymphoblastic Leukemia (1) Phase 1 (1) Colorectal Cancer (1)
other (3), mixed (1)
Hangzhou Converd (1) Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) Daihong Liu (1) M.D. Anderson Cancer Center (1)
BCMA (1) PDCD1 (1) IL13RA1 (1) EGFR (1) TGFBR2 (1) NR3C1 (1) TROP2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.